People ask about this all the time. Your own blood, spun for its platelets, at the clitoris and the anterior vaginal wall. The FDA has not approved platelet-rich plasma for this use, and the published evidence is small and mixed — which is better to know now than after you have paid for it.
Book a consultationSmall studies, mixed results
An intimate PRP injection places platelet-rich plasma from your own blood at the clitoris and the anterior vaginal wall. Where patients report a change, it appears between week 3 and week 12, reassessed at 8 to 12 weeks. The FDA has not approved platelet-rich plasma for either use, and published evidence is small and mixed.
Platelet-rich plasma is prepared from a blood sample. Its use for female sexual function and urinary incontinence is not FDA-approved. A consultation should explore the cause of your concerns and the options available to you.
Growth factors are the proposed mechanism, not a demonstrated outcome. Studies are small, mostly open-label; sham-controlled evidence is limited and mixed. Nothing is visible afterwards.
| Option | What it addresses | Regulatory status for this use | Typical onset | Typical duration | Downtime |
|---|---|---|---|---|---|
| Intimate PRP injection | Sensation, orgasm difficulty, mild stress incontinence | Not FDA-approved for this use. Preparation devices are cleared for producing PRP only | Reported at 3 to 12 weeks by patients who notice a change | Reported at roughly 6 to 12 months in small uncontrolled series. Not established | Same day back to activity, 48 hours before intercourse |
| Local vaginal estrogen | Dryness, tissue thinning, discomfort with penetration after menopause | FDA-approved for symptoms of vulvovaginal atrophy, including moderate to severe dyspareunia. Prescription only, and the labeling carries an FDA boxed warning | 2 to 12 weeks | Ongoing while it is used | None |
| Pelvic floor physical therapy | Stress urinary incontinence, pelvic floor dysfunction, pain with penetration | Not a drug or device. Supported by randomized trials as first-line care for stress incontinence | 6 to 12 weeks of sessions | Maintained with continued exercise | None |
| Energy-based vaginal devices | Marketed for laxity, dryness and incontinence | Cleared for other gynecologic uses. The FDA has warned manufacturers against marketing these claims | Weeks, after a series | Not established | Usually 2 to 3 days of restrictions |
| Hyaluronic acid filler to the labia | External volume and contour only, not sensation or continence | No hyaluronic acid filler carries FDA approval for labial placement, so this is off-label use of an approved filler | Immediate | Typically 9 to 12 months | Swelling for several days |
These options behave differently, and the cause of your symptom decides. Regulatory status reflects U.S. labeling.
Autologous platelet-rich plasma — Autologous means it comes from you. Platelet concentration varies by person and by preparation system, which is one reason results vary.
Closed PRP separation system and centrifuge — PRP preparation devices are FDA-cleared to produce platelet-rich plasma, in most cases for orthopedic or wound applications. Clearance of the device is not approval of the use described on this page.
Sodium citrate anticoagulant tube — Standard collection chemistry. The citrate travels with the draw, so trace amounts are present in what is injected.
Calcium chloride activator — Whether activation changes outcomes is unsettled. Which approach is used here is stated at the consultation.
Topical anesthetic and buffered lidocaine — Comfort measure. The numbing takes longer than the treatment, which is why the appointment runs an hour.
Nothing is injected today. Symptoms, medications, hormonal status and deliveries reviewed; bloodwork may be ordered.
An ordinary arm draw, spun in a centrifuge. 20 to 60 milliliters.
Topical anesthetic 20 to 30 minutes, then buffered lidocaine. Injections take under five minutes.
Change, where reported, appears weeks 3 to 12. Reassessment at 8 to 12 weeks.
It runs 45 to 60 minutes, and numbing takes most of it: topical for 20 to 30 minutes, then buffered lidocaine.
Week two tells you little. Where an effect is reported, it runs roughly six to twelve months. Those series are small and disagree; no duration is established.
Most patients describe pressure rather than pain. Topical anesthetic sits 20 to 30 minutes, then buffered lidocaine, so numbing takes longer than the treatment. Soreness settles within 24 to 72 hours.
No, and you should have that clearly before anything else. The FDA has not approved platelet-rich plasma for female sexual function or for urinary incontinence, and there is no approved label here for a use to sit off, which is why this is not described as off-label. The centrifuge systems that prepare it are FDA-cleared to produce platelet-rich plasma, in most cases for orthopedic or wound applications, and clearance of the device is not approval of what is done with the output. This is provider-directed use of an unapproved preparation, which the FDA regulates as a human cell and tissue product. Knowing exactly where it sits is part of choosing it.
The cost depends on your treatment plan. Call (614) 425-1633 for current pricing and ask what consultation, treatment, and follow-up charges apply.
Wait 48 hours. The interval gives the injection points time to close, not the plasma time to settle. Stop if anything is painful. Mild swelling for a day or two is expected.
Where an effect is reported, published series put the window at roughly six to twelve months. Those series are small. Some patients notice nothing at all, a documented outcome rather than a technique failure.
Mild stress urinary incontinence is leakage when abdominal pressure rises suddenly. Small open-label studies report improvement; sham-controlled evidence is limited and mixed, so no likelihood can be quoted. Pelvic floor physical therapy has stronger evidence and comes first.
Tell us what you take and why. Anticoagulation raises bleeding and bruising risk, and some agents cannot be safely paused, so this needs a conversation with the prescribing provider first. Bring the medication list. Sometimes the assessment is that the injection should not be done.
Both use platelet-rich plasma from your own blood. PRP microneedling applies it to the face after needling; the intimate PRP injection places it at the anterior vaginal wall near the urethra and at the clitoris.
No. Consultations are booked without a stated reason, the room is private, a chaperone is offered, and nothing is photographed. Reminders and card statements read Rouge Aesthetics. No anatomical imagery appears anywhere on this site.
Some patients report no change, a documented outcome rather than a technique failure. Platelet-rich plasma cannot be reversed; there is nothing to dissolve, and it resorbs on its own. The 8-to-12-week reassessment is where that is established.
Platelet-rich plasma is not FDA-approved for female sexual function or for urinary incontinence, and no platelet-rich plasma product carries an approved label for these uses. The FDA regulates platelet-rich plasma as a human cell and tissue product, and this page describes provider-directed use of an unapproved preparation rather than an approved indication.
Individual results vary and nothing on this page promises a specific result. Platelet-rich plasma does not correct a hormonal, medication-related or neurologic cause, and some patients report no change at all.
No energy-based device is cleared or approved by the U.S. Food and Drug Administration for vaginal rejuvenation, and the FDA issued a safety communication on that marketing in 2018. Rouge Aesthetics owns no such device and does not refer for one.
Rouge Aesthetics · 101 Mill Street, Suite 210, Gahanna, OH 43230 · (614) 425-1633
Individual results vary. This website provides general information and does not replace an individual consultation.